The firm saw total revenues of $859,526 for the three months ended Dec. 31, 2018 compared to $995,226 in the same period of 2017.
The platform, from a University of Illinois at Chicago-led team, separates circulating tumor cells from other cell types using size-dependent inertial migration.
At the AGBT meeting last night, Johns Hopkins researcher Joshua Cohen said that the partners are looking to recruit 50,000 healthy individuals for the study.
Research groups and companies are developing and applying tools to enrich for and capture CTCs to diagnose tumors early and monitor patients during treatment.
The team will combine CellMax's circulating tumor cell platform and Medigen's liquid biopsy panel to track treatment response in colorectal cancer patients.
Stratec is producing the microfluidic chips for Vortex' VTX-1 system, which enables the enrichment and isolation of circulating tumor cells.
Epic Sciences will donate its No Cell Left Behind platform to the clinical trial, which will enroll about 1,000 patients over three years.
The decision, issued by Medicare Administrative Contractor Palmetto GBA, is effective Dec. 10 and provides coverage of the test for about 25,000 Medicare patients.
The move will gain PFM a Houston lab, as well as ApoCell's proprietary ApoStream liquid biopsy technology for isolation and capture of circulating tumor cells.
The long-running Framingham Heart Study has received a $38 million grant, according to the Boston Globe.
A Stanford University investigation finds that its researchers did not take part in He Jiankui's work to develop gene-edited infants.
Retraction Watch reports that two researchers had both a Science and a Nature paper retracted last week.
In Genome Biology this week: genomic sequencing of milkweed bug, benchmark comparison of single-cell RNA sequencing platforms, and more.